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Abstract
The Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association
[APA], 2000) estimates that in the United States, Posttraumatic Stress Disorder (PTSD) affects
8% of adults at some point during their life. Nightmares have a severe impact and can cause
great distress for individuals with PTSD (Ohayon & Shapiro, 2000). Spoormaker and
Montgomery (2008) suggested that sleep problems may be more of a risk factor for PTSD then a
symptom of the disorder. Either way, it is evident that sleep needs to be addressed in those with
this diagnosis. Posttraumatic nightmares are seldom the topic of PTSD studies utilizing
medication management (Spoormaker & Montgomery) even though the rates of this symptom
can be high. According to Friedman (2002), the use of psychiatric medication has shown
minimal positive results in improving sleep issues.

It has been suggested that prazosin may be

beneficial in decreasing posttraumatic nightmares (VA, 2010). A literature review was
completed to determine the effectiveness prazosin had on decreasing posttraumatic nightmares
compared to a placebo, no medication, or psychotropic medications. Other studies including
qualitative research were incorporated to show other responses related to the medication. These
studies all shared results indicating that prazosin is effective at decreasing the quantity and
intensity of nightmares in the adult populations studied. This information was disseminated
through a presentation to mental health staff on an inpatient psychiatric unit. Discussion and
review allowed for feedback from the staff. They gave examples of cases they’ve experienced
and agreed that prazosin can be a useful medication in the treatment of posttraumatic nightmares.
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Introduction
The Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric
*'^*^s’sociation [APA], 2000) estimates that in the United States, Posttraumatic Stress Disorder
(PTSD) affects 8% of adults at some point during their life. PTSD is defined as “characteristic
symptoms following exposure to an extreme traumatic stressor” (APA, p. 463). These stressors
can include physical and sexual abuse or attacks, military warfare, disasters, terrorism, injury,
and death, and the symptoms can include flashbacks, nightmares, avoidance of situations or
stimuli, and heightened awareness of the environment. The focus in this discussion is on
nightmares because of the distress and severe impact they can cause for people with PTSD
(Ohayon & Shapiro, 2000). Spoormaker and Montgomery (2008) suggested that sleep problems
may be more of a risk factor for PTSD then a symptom of the disorder. Either way, it is obvious
that sleep needs to be addressed in those with this diagnosis.
The prevalence of nightmares or distressing dreams and PTSD varies based on the
population of study. Sixty-seven percent of Vietnam veterans with PTSD had nightmares
(Holowka, Marx, Kaloupek, & Keane, 2012). A study focused on PTSD in the general
population showed a 72% prevalence of nightmares among its individuals (Leskin, Woodward,
Young, & Sheikh, 2002). The lifetime prevalence of PTSD and a comorbid psychiatric
diagnosis was 88% in males and 79% in females (Kessler, Sonnega, Bromet, Hughes, & Nelson,
1995). Up to 96% of individuals with PTSD and a comorbid disorder experienced nightmares
(Leskin et al ). It has been suggested that prazosin may be beneficial in decreasing posttraumatic
nightmares (VA, 2010).
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Purpose
The purpose of this project is to determine the effects that prazosin has on nightmares in
individuals with a diagnosis of PTSD. Nightmares are seldom a topic in health education (Stores
& Crawford, 1998). They are viewed as secondary to PTSD, and it is rare that sleep disturbances
are monitored and treated after PTSD has resolved (Spoonnaker & Montgomery, 2008). The
psychotropic medications considered first-line agents to treat this mental illness have not been
shown to be effective in treating posttraumatic nightmares (Davidson, Rothbaum, van der Kolk,
Sikes, & Farfel, 2001; Meltzer-Brody, Connor, Churchill, & Davidson, 2000). It is important to
find medications that have evidence based efficacy that practitioners can have confidence in
prescribing.
The utilization of more effective medication management methods can help increase the
quality of life that those with PTSD experience, and it can reduce the number of nightmares and
the number of people who deal with posttraumatic nightmares. After a literature review was
conducted, a presentation (See Appendix) focused on this topic was presented to professionals in
the psychiatric field.
Significance
Almost three quarters of the civilian population with PTSD and 96% ot individuals with
PTSD and a comorbidity experienced nightmares (Leskin et al., 2002). In a study by Davis,
Byrd, Rhudy, and Wright, (2007) it was reported that individuals can experience distressing
dreams multiple times in a week or night, and the nightmares can lead to an increase in distress
related to “global sleep quality” and a dread of falling asleep. Nightmares can cause repeated
awakenings throughout the night or avoidance of sleep, and this can lead to “excessive
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sleepiness, poor concentration, depression, anxiety, or irritability that can disrupt daytime
functioning” (APA, 2000, p. 631).
Many people with this diagnosis experience distressing dreams and they can occur quite
frequently, but only 14 controlled trials with placebos have been conducted considering the use
of medications on sleep symptoms of PTSD (Spoormaker & Montgomery, 2008). Selective
serotonin reuptake inhibitors (SSRIs) are considered first line treatments for PTSD, but they have
been shown to cause problems with sleep and have little to no benefits for nightmares (Friedman,
2002; Davidson et al., 2001; Meltzer-Brody et al., 2000). Prazosin has shown potential in aiding
the relief from posttraumatic nightmares (Crenshaw, 2010).
Individuals with posttraumatic nightmares may seek treatment and care through primary
physicians and psychiatric physicians and practitioners. Those that will be most impacted by this
information are practitioners in psychiatry, general medicine, and public health in both acute and
outpatient settings. Reviewing the literature has led to insight about the promise behind the use
of prazosin on treating posttraumatic nightmares. This information is useful for clinical practice
where clients are seeking care for their symptoms of PTSD.
Theoretical Framework
The Roy Adaptation Model was used for this project to help guide and understand the
topic of study. Understanding adaptation to stimuli in a person’s life can help understand how to
deal with and treat these stressors or stimuli. Individuals diagnosed with PTSD are considered
by Roy and Andrews (1999) to be adaptive systems. The stimuli have an effect on the
individual’s life. The influence of stimuli leads to an attempt to adapt. The adaptive response
which includes innate and acquired mechanisms is viewed as effective or dysfunctional. If the
change is not in a positive direction and the adaptation is not effective, an active examination by

PRAZOSIN EFFECTS ON POSTTRAUMATIC NIGHTMARES

6

the nurse to recognize, understand, and respond to human coping processes should be completed
(Roy & Andrews, 1999). To help the individual, the nurse should also perform an assessment of
behaviors and influencing factors, determine a nursing diagnosis, perform goal setting, determine
an intervention, and complete an evaluation (Roy, 1984). Goals of the Roy Adaptation Model
include increasing effective adaptation and reducing ineffective reactions (Roy, 1984). By using
prazosin to treat posttraumatic nightmares, the nurse is responding to the ineffective coping the
individual is experiencing.
The Roy Adaptation Model focuses on a holistic approach and emphasizes the biological,
psychological, and social factors that can affect a person’s response to traumatic events (Roy &
Andrews, 1999). The four areas to be considered include physiologic needs, self-concept, role
function, and interdependence (Roy & Roberts, 1981). The use of medication management for
nightmares can be considered a form of managing the stimuli in a biological and physiologic
manner.
Definitions
A few terms used throughout this paper will be defined in this section so the topic of
discussion can be comprehensively understood.
PTSD
According to the DSM, PTSD is a mental disorder that involves an experience or contact
with an extreme traumatic stressor that included possible death, injury, or a danger to self or
others. The individual who experienced the traumatic event responds with extreme fear,
helplessness, or horror. Criteria in the DSM include re-experiencing the trauma, avoiding stress
or stimuli related to the trauma, and persistent increased arousal. To be diagnosed with PTSD,

PRAZOSIN EFFECTS ON POSTTRAUMATIC NIGHTMARES

7

symptoms are present for longer than one month, and the symptoms cause social and
occupational impairment or severe distress in the person’s life (APA, 2000).
Nightmare
Nightmare has been defined as “a frightening dream that usually awakens the sleeper”
(Merriam-Webster, 2012). According to the Mayo Clinic (2011), nightmares are “disturbing
dreams associated with negative feelings, such as anxiety or fear.” Nightmares are also defined
as “a bad dream that brings out strong feelings of fear, terror, distress, or anxiety” (MedlinePlus,
2012). During distressing dreams related to PTSD, the traumatic episode can be repeated or
symbolized (APA, 2000).
Prazosin
Prazosin is an alphai adrenergic receptor antagonist that is most often clinically used to
treat hypertension. In adults the recommended initial dose for hypertension is one to two
milligrams two to three times a day. The maintenance dose for hypertension is 6 to 15 mg/day
over two or three divided doses. The suggested titration is lmg. Due to its effect on blood
pressure, it is recommended to give this medication at bed time to decrease the risk of orthostatic
hypotension (Wynne, Moser Woo, & Olyaei, 2011).
Adult
The DSM acknowledges that PTSD can affect individuals of all ages (APA, 2000). It is
important to recognize differences between children and adolescents compared to adults, so the
population of interest in this project is adults age 18 years and older.
Review of the Literature
Although there are FDA approved first-line treatments for PTSD, there are not
medications specifically designed for PTSD and nightmares (Friedman, 2002). It is important to
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explore other options outside of SSRIs in treating distressing dreams, because they can have such
an impact on a person’s life.
There is an increasing amount of literature focused on the use of prazosin to treat
posttraumatic nightmares. The literature is expanding and includes qualitative, retrospective,
open trials, and randomized controlled trials (RCTs). By reviewing past studies, a
recommendation on the use of prazosin for adults diagnosed with PTSD experiencing nightmares
can be developed.
Five articles that were reviewed are RCTs that compared prazosin to placebos (Germain,
2012; Raskind et al., 2003; Raskind et al., 2007 Taylor et al., 2008; van Liempt, 2012). One of
these RCTs compared prazosin to a cognitive-behavioral treatment and a placebo (Germain).
Four open-label clinical trials looked at the effectiveness of prazosin on nightmares (Peskind,
Bonner, Hoff, & Raskind, 2003; Raskind et al., 2000; Taylor & Raskind, 2002; Thompson,
Taylor, McFall, Barnes, & Raskind, 2008). Two qualitative (Gehrman & Harb, 2010; Johnson,
& Rosen, 2013) and two retrospective chart reviews were found (Boynton, Bentley, Strachan,
Barbato, & Raskind, 2009; Raskind et al., 2002).

A retrospective chart review on comparing

prazosin to quetiapine was also reviewed (Byers, Allison, Wendel, & Lee, 2010).
Prazosin was shown to be effective at decreasing nightmares in individuals diagnosed
with PTSD who were veterans (Germain, 2012; Peskind et al., 2003; Raskind et al., 2000,
Raskind et al., 2002; Raskind et al., 2003; Raskind et al., 2007; Thompson et al., 2008) and
nonveterans (Gehrman & Harb, 2010; Johnson, & Rosen, 2013; Taylor et al., 2008; Peskind et
al., 2003; Taylor & Raskind, 2002). All of the studies included males. Four studies specified
female participants were involved in their studies (Gehrman & Harb, 2010; Raskind et al., 2007;
Taylor et al. 2008; Taylor & Raskind, 2002). The number of female subjects was low in the
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studies they did participate in. Raskind and colleagues (2007) had two female participants out of
forty, and Byers and colleagues (2010) had 2% of the 237 participants that were females. One
study was composed of 11 females out of 13 (Taylor et al.). One RCT that studied PTSD in
veterans stated 26 white, 11 African-Americans, and one Asian-American, Hispanic, and Native
American were involved in their study (Raskind et al., 2007). Boynton and associates (2009)
stated their refugee subjects were from Afghanistan, Cambodia, Ethiopia, Gambia, Iraq, Kosovo,
Somalia, and Vietnam.
Studies included various numbers of participants. The RCTs included ten male Vietnam
combat veterans (Raskind et al., 2003), forty veterans from the Vietnam War, World War II,
Korean War, Panama invasion, and Gulf War (Raskind et al., 2007), fifty veterans (Germain,
2012) , and thirteen civilian individuals which included eleven females (Taylor et al., 2008). One
open trial included four participants (Raskind et al., 2000). An open trial focused on prazosin’s
effects of posttraumatic nightmares in an elderly population had nine male participants that
included World War II, Korean War, and World War II veterans. The ninth participant was a
Holocaust concentration camp survivor (Peskind et al., 2003). The qualitative studies each had
case illustrations that were based on one individual (Gehrman & Harb, 2010; Johnson, & Rosen,
2013) . Twenty-three individuals were included in a retrospective chart review on refugees
(Boynton et al., 2009). A placebo controlled study that included civilian participants had
eighteen subjects initially, but two withdrew due to orthostatic hypotension with a lmg initial
test of the medication, one relocated, and two withdrew after deciding not to participate. Fiftynine Vietnam and Gulf-war combat veterans were included in another retrospective chart review.
Of the 59, only 36 completed an eight week treatment course of prazosin (Raskind et al., 2002).
In the retrospective chart review that compared prazosin to quetiapine, a total of 237 participants
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were included, with 62 who were administered prazosin, and 175 who were administered
quietiapine (Byers, et al., 2010).
Average ages of the randomized controlled trials were 53 years (Raskind et al., 2003), 56
years (Raskind et al., 2007), 49 years (Taylor et al., 2008), and 41 years (Germain, 2012). The
average age of veteran males in an open clinical trial was 57 years (Raskind et al., 2000). The
refugees in the retrospective chart review had an average age of 30.3 years (Boynton et al.,
2009), while another chart review on combat veterans had an average of 51 years (Raskind et al.,
2002). The qualitative study involving the man who went to a nursing home was 86 years of age
(Johnson, & Rosen, 2013), and another qualitative study stated the woman was in her “mid-50s”
(Gehrman & Harb, 2010). The retrospective study comparing two medications had an average
age of participants of 53 years for the quetiapine group and 54 for the prazosin group (Byers, et
al., 2010).
All studies reviewed required that individuals be diagnosed with PTSD based on DSM
criteria. In Taylor and colleagues’ (2008) placebo controlled trial with civilian individuals,
limitations included that the individuals were healthy and had no substance abuse issues for the
three months prior to the study. Taylor and Raskind performed an open label trial in 2002 with
civilians and Raskind and colleagues (2000) performed an open label trial with four combat
veterans. In both of these, the subjects had not experienced substance or alcohol abuse six
months prior to the study. Raskind and colleagues’ (2003) RCT focused on ten Vietnam
veterans, and they did not have alcohol or substance abuse for six months prior to the study. In
the retrospective chart review on a refugee population, no individuals had been diagnosed with
substance abuse or dependence (Boynton et al., 2009).
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Of these studies, some discussed the comorbid psychiatric conditions the individuals with
PTSD experienced (Boynton et al., 2009; Gehrman & Harb, 2010; Taylor et al., 2008, Thompson
et al., 2008). An open-trial with nine elderly participants stated that all participants had more
than one medical diagnosis. Some comorbidities listed included cerebrovascular disease, atrial
fibrillation, hypertension, gout, congestive heart failure, osteoporosis, diabetes mellitus,
gastroesophageal reflux disease, and hypothyroidism (Peskind et al., 2003). Raskind and
colleagues (2007) excluded those with a prior diagnosis of schizophrenia, bipolar disorder,
psychotic disorder, or depression with active suicidal thoughts. In some instances, participants
continued psychotherapy during the study with prazosin (Raskind et al., 2007; Taylor et al. 2008;
Thompson et al., 2008). Psychotropic medications were continued throughout some studies
unchanged (Boynton et al. 2009; Byers et al., 2010; Peskind et al. 2003; Raskind et al., 2002;
Raskind et al., 2003; Raskind et al., 2007; Taylor et al., 2008; Thompson et al., 2008).
Medication differences were noted between the two groups who took prazosin and who took
quetiapine. Fourteen percent fewer of those taking quetiapine were administered a sleep
medication at baseline, and 80% of those taking quetiapine compared to 61% taking prazosin
were on an SSRI at some point during the duration of study (Byers et al., 2010).
Posttraumatic stressors varied. In one RCT that was a double blind, crossover study,
various past traumatic stressors included childhood sexual or physical abuse, adult assault, rape,
and a life-threatening motor vehicle accident (Taylor et al., 2008). In other studies the stressor
was combat and war (Raskind et al., 2000; Raskind et al., 2002; Raskind et al., 2003). In the
retrospective chart review on a refugee population, stressors included observing war, witnessing
murders of family, rape, torture, being a war hostage, and being captured by soldiers and then
experiencing physical and sexual abuse (Boynton et al., 2009). The 86 year old man
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transitioning to a nursing home was a Holocaust survivor (Johnson, & Rosen, 2013). The
woman in the case illustration had experienced childhood sexual abuse (Gehrman & Harb,
2010). One article included the length ofPTSD symptoms (Boynton et al.) while most did not
address this.
Various dosing was found to be effective for participants. As low as 2 to 4mg/day
decreased traumatic nightmares in elderly veterans (Peskind et al., 2003), and 2 to 6mg/day
(Taylor et al., 2008) and 1 to 4mg/day (Taylor & Raskind, 2002) decreased nightmares in
nonveterans. In the RCT comparing prazosin, cognitive-behavioral therapy, and a placebo, the
participants had an average dose of 8.9mg/daily (Germain, 2012). Two of the participants in an
open clinical trial with four veterans reached a dose of 5mg/day and the other two were restricted
to 2mg/day due to issues with low blood pressure (Raskind et al., 2000). The elderly man who
was the focus of one qualitative study took lmg/day of prazosin (Johnson, & Rosen, 2013). The
women in the qualitative case illustration took an ending dose of 9mg at bedtime (Gehrman &
Harb, 2010). An average of 9.5 mg/day (Raskind et al., 2003), 9.6mg/day (Thompson et al.,
2008), and 13mg/day of prazosin (Raskind et al., 2007) produced a reduction in nightmares in
veterans with PTSD. In a refugee population an average dose of 2.3mg/day that ranged from one
to six mg/day for participants was utilized (Boynton et al., 2009), and in a population of combat
veterans, of the 36 who completed a week course of prazosin, the average dose was 9.6mg/day
(Raskind et al., 2002). The comparison of prazosin versus quetiapine had various doses listed
depending on the time of the study. After half a year of prazosin administration, the average
dose was 3.2mg/day. At the end of the study the average was 6.3mg/day with a range of one to
25mg/day. Quetiapine dosing averaged 10lmg/day at six months and 135mg/day at the end of
the study. The range was from 25 to 600mg/day (Byers et al., 2010).
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A couple of the RCTs were double blind crossover trials that lasted seven weeks (Taylor
et al., 2008) and 20 weeks (Raskind et al., 2003). A RCT including randomization to a prazosin,
therapy, or placebo group (Germain, 2012) and a RCT including randomization to prazosin,
quetiapine, or placebo group lasted eight weeks (Byers et al., 2010). An open trial that had four
veterans participate (Raskind et al., 2000) and two retrospective chart studies of refugees and
combat veterans lasted an eight week period (Boynton et al., 2009; Raskind et al., 2002).
Although only a week of prazosin use in an elderly man was discussed in a qualitative study, his
nightmares stopped (Johnson, & Rosen, 2013).
To measure the outcomes prazosin had on traumatic nightmares, the Clinician
Administered PTSD Scales (CAPS) Recurrent Distressing Dream was used (Boynton et al.,
2009; Peskind et al., 2003; Raskind et al., 2000; Raskind et al., 2002; Raskind et al., 2003;
Raskind et al., 2007; Taylor et al., 2008; Thompson et al., 2008). The CAPS PTSD nightmare
item was also used (Germain, 2012; Raskind et al., 2003; Taylor & Raskind, 2002). The Clinical
Global Impression of Improvement (CGI-I) was used in multiple studies to measure outcomes on
nightmares (Boynton et al., 2009; Germain; Raskind et al., 2000; Raskind et al., 2002; Raskind
et al., 2003; Taylor et al., 2008). In the qualitative studies the participants were asked about their
number of nightmares. The female stated her nightmares decreased from nightly to one to two
every week and the elderly male stated his ceased all together (Gehrman & Harb, 2010; Johnson
& Rosen, 2013).
All of the studies discussed in this paper concluded that prazosin is effective at helping to
treat posttraumatic nightmares. Prazosin and quetiapine had comparable success in decreasing
nightmares in a short period of time. Byers and fellow researchers (2010) concluded that the
prazosin had a higher probability to be continued until the end of the study when compared to
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quetiapine. Some people continued it up to six years following the start of the study. They
stated that the quetiapine participants who stopped taking the medication were more likely to
discontinue it due to side effects or lack of efficacy. A decrease in the number of nightmares
with both prazosin and cognitive-behavioral therapy were clinically significant and greater than
that of placebo, but there was a decrease in all three groups over a period of time (Germain,
2012 ).

Methods
A literature search was performed to find studies related to the topic of this project. The
search was completed through the University of North Dakota’s Harley French Library website
with the use of CINAHL, Cochrane Library, and Psychlnfo. These were preferred due to the
topic of interest being reviewed. The Cochrane Library and CINAHL provide highly regarded
reviews, and Psychlnfo provides studies with a focus on psychology (Mateo & Kirchhoff, 2009).
Limitations included retrospective studies, randomized controlled trials, open trials, and
qualitative studies that were published in English after 2000. The limitation on year was used
because of the importance of current data.
The terms used in CINHAL’s headings included PTSD or posttraumatic stress disorder,
prazosin, and nightmares or distressing dreams. This returned seven studies for review. The
years were not limited due to the available studies being completed in 2003 or later. Of the
seven studies, three of the articles appeared to meet criteria for this topic.
The same terms were used in the medical subject heading on the Cochrane Library site.
This resulted in three reviews of which one was a repeat and one appeared to match criteria.
Psychlnfo’s thesaurus was used in an attempt to find search terms that matched the research
question. The same terms were used as above. Psychlnfo produced 33 search results from 2000
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to the present. Thirteen articles were noted to be suitable for the research question. Of these
appropriate articles, four were repeats from the previous search.
The references of the articles chosen were reviewed and one further article was found to
be appropriate for the use of this study review. The others that did appear suitable were repeated
results from the searches listed previously. The total number of research articles that appear to
meet criteria is fourteen.
The data compiled here was presented to a group of staff who treat people with a
diagnosis of PTSD that experience posttraumatic nightmares in a local inpatient setting.
Individuals were given handouts bulleting the rationale for this study and the implications of it
(See Appendix). After the information was distributed, there was time for discussion, questions,
and recommendations for current treatment of posttraumatic nightmares on the unit.
Results
Following the presentation, the mental health professionals were asked for their feedback
and thoughts related to the topic. These professionals had knowledge of prazosin and had
administered it before. A couple of staff'members shared patient successes with prazosin and
also discussed and agreed that further research on dosing and diversity were necessary. All of
these professionals had witnessed individuals have a decrease in the number and intensity of
posttraumatic nightmares with the use of prazosin. Some had noted that in other cases they
weren’t able to witness effects and results due to the patient being discharged or due to side
effects of orthostatic hypotension. Staff'brought up a concern that providers did not dose
prazosin high enough to be effective. They stated in some cases the medication was maxed at
approximately 2mg even though side effects were not present. The participants of this
presentation agreed that further research on dosing and diversity were necessary. They all
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recognized the importance of assessing the effectiveness of prazosin on posttraumatic nightmares
in those hospitalized on the inpatient psychiatric unit.
Discussion and Implications for Nursing
Posttraumatic nightmares are seldom the topic of PTSD studies utilizing medication
management (Spoormaker & Montgomery, 2008) even though the rates of this symptom can be
high. According to Friedman (2002), the use of psychiatric medication has shown minimal
positive results in improving sleep issues. SSRIs and selective norepinephrine reuptake
inhibitors are considered to be first-line medications for this disorder, but they can cause side
effects such as sleep problems (Stahl, 2008). SSRIs such as sertraline lead to increased insomnia
and sleep problems (Davidson, Rothbaum, van der Kolk, Sikes, & Farfel, 2001). Fluoxetine did
not show better efficacy then a placebo on decreasing nightmares (Meltzer-Brody, Connor,
Churchill, & Davidson, 2000). Cyproheptadine, an antihistamine, had mixed results. Two
studies showed a benefit in decreasing nightmares, but another showed that it could worsen
nightmares (Brophy, 1991; Jacobs-Rebhun et al., 2000; Rijnders, Laman, & Van Diujn, 2000).
These medications are not relieving nightmares in those with PTSD at a high enough rate and at
times they are causing further sleeping issues.
Due to the lack of effective medication that was previously thought to eliminate or
diminish PTSD nightmares, it is important to review the studies on prazosin that have been
completed. From the data provided by them, there is hope with this medication for those
suffering from posttraumatic nightmares. Nursing can use this information to make a difference
for those with distressing dreams.
The Roy Adaptation Model directs nurses to look at the changes occurring in an
individual’s life. If it is not in a therapeutic direction, an active examination needs to be
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performed by the nurse. The nurse should try to understand and identify methods to treat
maladaptive processes after they recognize the patient is in distress (Roy & Andrews, 1999).
Nightmares need to be understood from the patient’s point of view and an assessment of quality,
duration, and number of nightmares needs to be determined so a baseline is developed for
comparison. The nurse should also have an ability to assess the patient’s previous attempts to
treat posttraumatic nightmares.
It is at this point that nurses are then able to help the patient increase effective adaptation
with the knowledge from the multiple research approaches discussed previously. These various
approaches which include qualitative studies, open trials, retrospective chart reviews, and RCTs
have shown that prazosin is effective in various groups at decreasing distressing dreams related
to trauma. Due to this knowledge, it is apparent that the use of prazosin can be considered a
method to assist the individual in increasing this effective adaptation.
Results show that nightmares decrease for many people diagnosed with PTSD who are
prescribed prazosin. An issue that may come up related to prescribing this medication is dosing.
There are various dosages throughout the studies and research that have been found to be
effective for distressing dreams. This can lead to confusion for prescribing the medication. It is
important to look at the methods that the studies have utilized in medication administration, but
until further research is completed on the appropriate initial dosing and titration patterns for
posttraumatic nightmares, it may be useful to follow the recommendations on prescribing for
hypertension. An initial dose of 1mg/day is recommended, and it is suggested it then be titrated
in small increments of lmg, while monitoring for side effects such as orthostatic hypotension
(Wynne et al. 2011). This is similar to many of the methods used throughout the studies
discussed in the literature review section.

PRAZOSIN EFFECTS ON POSTTRAUMATIC NIGHTMARES

18

Further research is necessary to be able to generalize results to even more diverse
populations. Veterans and nonveterans have been included in these studies, but few women are
included as participants compared to the number of men. Many of the studies were performed in
older populations, so young and middle aged adults may not have the same response that was
shown in these participants. It is also important to assess the usefulness of prazosin in even
younger patients such as children and adolescents since PTSD can affect individuals of all ages,
including children (APA, 2000).
Two studies comparing prazosin to other treatment methods were found through the
literature search. It is important to further the research that supports the use of prazosin
compared to other medications and therapy to know if it should be considered a first line drug for
treatment of posttraumatic nightmares. In the studies quetiapine was shown to be as effective as
prazosin, but the discontinuation rates was higher for quetiapine due to side effects and perceived
lack of efficacy (Byers et al., 2010). It is necessary to monitor individuals’ reactions and side
effects to the medication, especially as it is increased. Many of the studies point out that the side
effects of prazosin are quite low and this is a reason it has such great potential in clinical
practice. Nightmares returned in some people when the medication was discontinued (Raskind
et al., 2003). It is necessary7to educate patients on this so they realize that if they stop the
prazosin, their nightmares may return.
Education needs to be provided on the use of prazosin and its helpfulness with
posttraumatic nightmares. Inpatient and outpatient prescribing practitioners should be made
aware of the results that have been found related to this medication’s use. Clinical effectiveness
will need to be considered for each individual.
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Conclusion
PTSD is a prevalent problem in the psychiatric field. The number of individuals
diagnosed with PTSD who experience nightmares is high. Nightmares can be recurrent and
distressing to individuals. They can lead to dysfunction in daily living. Management of these
distressing dreams can be difficult to target with current recommended medications for this
diagnosis. The nightmares can persist even after first line medications treat the other symptoms
of PTSD. Individuals can experience negative effects related to nightmares that can severely
impact their lives.
Through multiple studies, prazosin was shown to decrease intensity and frequency of
posttraumatic nightmares in various populations, including veterans, nonveterans, males,
females, and elderly. Future research with an even more diverse population will determine if
these results will be replicated in other groups. Nursing can help recognize the adaptations and
stressors that influence PTSD nightmares and realize the need for an effective adaptive treatment
to decrease stress. Every individual experiences symptoms in differing ways, but the
prescribing of prazosin for adults with PTSD experiencing posttraumatic nightmares should be
considered an important tool of treatment.
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Prazosin Effects on Posttraumatic Nightmares
Laurie Tefft

Topic: In adults with PTSD, how does prazosin compare to a placebo, no medication, or a
psychotropic in decreasing posttraumatic nightmares?

What is PTSD?
• A mental disorder that involves an
experience or contact with an
extreme traumatic stressor that
included possible death, injury, or a
danger to self or others.
• Individual responds with extreme
fear, helplessness, or horror.
• Criteria include re-experiencing the
trauma, avoiding stress or stimuli
related to the trauma, and persistent
increased arousal.
• Symptoms are present for longer
than one month, and they cause
social and occupational impairment
or severe distress in the person’s life
(APA, 2000).
What is a nightmare?
• “A frightening dream that usually
awakens the sleeper” (MerriamWebster, 2012).
• “Disturbing dreams associated with
negative feelings, such as anxiety or
fear” (Mayo Clinic, 2011).
• “A bad dream that brings out strong
feelings of fear, terror, distress, or
anxiety” (MedlinePlus, 2012).
• The traumatic episode can be
repeated or symbolized (APA,
2000 ) .

What is Prazosin?
• An alphai adrenergic receptor
antagonist that is most often
clinically used to treat hypertension.
• In adults the recommended initial
dose for hypertension is one to two
milligrams two to three times a day.
(Wynne, Moser Woo, & Olyaei,
2011 ) .

What is the importance of studying
posttraumatic nightmares?
• PTSD affects 8% of adults at some
point during their lives (APA, 2000).
• In the general population with PTSD,
72% of individuals experience
nightmares (Leskin, Woodward,
Young, & Sheikh, 2002).
• Up to 96% of individuals with PTSD
and a comorbid disorder experienced
nightmares (Leskin et al., 2002).
• First-line psychotropics used to treat
PTSD have not been shown to be
effective in treating posttraumatic
nightmares (Davidson, Rothbaum,
van der Kolk, Sikes, & Farfel, 2001;
Meltzer-Brody, Connor, Churchill, &
Davidson, 2000).
• There are no specific medications
that target posttraumatic nightmares
(Friedman, 2002).
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What effects did prazosin have on
nightmares?
• Through various study approaches,
including randomized controlled
trials, open trials, retrospective
studies, and qualitative studies,
various prazosin doses were shown
to decrease the number of
nightmares that individuals
experienced. In some cases,
prazosin eliminated nightmares
completely for individuals.
What
•
•
•
•

populations were studied?
Combat veterans and nonveterans
Males and females
Refugees
Elderly

What future research should be
considered?
• Further research is necessary to be
able to generalize results to even
more diverse populations. Veterans
and nonveterans have been included
in these studies, but few women are
included as participants compared to
the number of men.
• Many studies were performed in
older populations, so young and
middle aged adults need to be the
focus of future research. It is also
important to assess the usefulness of
prazosin in even younger patients
such as children and adolescents
since PTSD can affect individuals of
all ages, including children (APA,
2000 ).

•

Various dosages have been found to
be effective to decrease nightmares.

•

2

It may be useful to follow the
recommendations on prescribing for
hypertension until further research
on suggested dosing ranges from
posttraumtic nightmares is
established. An initial dose of
lmg/day is recommended. It is
suggested it then be titrated in small
increments of lmg, while monitoring
for side effects such as orthostatic
hypotension (Wynne et al. 2011).
Two studies comparing prazosin to
other treatment methods were found.
It is important to further the research
that supports the use of prazosin
compared to other medications and
therapy to know if it should be
considered a first line drug for
treatment of posttraumatic
nightmares.

How can we use this information?
• Every individual experiences
symptoms in differing ways, but the
prescribing of prazosin for adults
with PTSD experiencing
posttraumatic nightmares should be
considered an important tool of
treatment.
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